William Whyte, MD
Interventional Pain Medicine · Shreveport, LANPI 1821060476
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $28,514 of the $38,874 with a category attached, or 73.3%. Medtronic accounts for 94.0% of it on its own, with 6 other manufacturers making up the rest. Among interventional pain medicine clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 161 payments — averaging $241.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$37K
- Si-bone, Inc.$2K
- Abbott$211
- Boston Scientific$116
- Amgen$66
- Avanos Medical$20
- plus $19 from 1 others
What the payments were for
- Speaking & faculty fees$28,51473%
- Travel & lodging$5,75915%
- Food & beverage$4,60112%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 123 | $36,538 |
| Si-bone, Inc. | 18 | $1,904 |
| Abbott | 8 | $211 |
| Boston Scientific | 5 | $116 |
| Amgen | 5 | $66 |
| Avanos Medical | 1 | $20 |
| Eagle Pharmaceuticals, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTELLIS ADAPTIVESTIM$33,917
- IFUSE IMPLANT SYSTEM$1,133
How this compares
$38,874 in reported general payments places this provider in the 90th percentile of 57 interventional pain medicine providers in Louisiana.
See all interventional pain medicine providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fentanyl | 12 | $2,737 |
| Tizanidine Hcl | 123 | $1,190 |
| Gabapentin | 87 | $653 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 35 | $261 |
| Tramadol Hcl | 73 | $242 |
| Celecoxib | 15 | $207 |
| Clindamycin Hcl | 23 | $88 |
| Ciprofloxacin Hcl | 12 | $48 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Shreveport
- John CefaluShreveport$71K
- Randall BrewerShreveport$19K
- Jefferey AdairShreveport$5K
- James WagesShreveport$3K
- Jai MunjampalliShreveport$3K
- Maged GuirguisNew Orleans$565K
- Suneil JollyKenner$107K
- Steve LeeSlidell$57K
- Paul HubbellMetairie$33K
- Ken EhrhardtHammond$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.